Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.81 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5652171 | 0.99 | NOS2 (0.79) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL6505773 | 0.90 | NOS2 (1.00) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL5649165 | 0.85 | NOS2 (0.61) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL5667983 | 0.84 | NOS2 (0.60) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL5648745 | 0.84 | SLC6A2 (0.70) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Hydrochloric Acid SCHEMBL5650489 | 0.83 | SLC6A2 (0.68) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6494424 | 0.81 | NOS2 (1.00) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| Fumaric Acid SCHEMBL6494416 | 0.81 | NOS2 (1.00) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 | |
| SCHEMBL5651711 | 0.81 | NOS2 (0.54) | NOS2CYP2D6SLC6A2SLC6A4CHRNB2 | |
| SCHEMBL6494143 | 0.81 | SLC6A4 (0.72) | NOS2CYP2D6SLC6A2SLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223794-B2 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | claimed |
| EP-1572068-A2 | ARYLHETEROALKALYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | claimed |
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | US | claimed |
| WO-2003011210-A2 | ARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | claimed |
| US-7223794-B2 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2007-05-29 | — | — | US | disclosed |
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143379-A1 | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | CYP1A1, NOS3, NOS1 | NOS2 5/4885CYP2D6 39/4885SLC6A2 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.